Protalix is a publicly traded biotechnology company
(NYSE Amex: PLX),
that is producing recombinant therapeutic proteins through the ProCellEx™ plant cell system.
ABOUT US
Corporate Profile
Market Needs
Protalix Advantage
Management Team
Scientific Advisory Board
Press Room
Careers
TECHNOLOGY
ProCellEx Overview
Platform Technology
Protein Production
PRODUCT DEVELOPMENT
taliglucerase alfa (UPLYSO)
Pipeline Products
PARTNERSHIPS
INVESTOR RELATIONS
Corporate Strategy
Management Team
Board of Directors
Stock Information
Corporate Governance
Filings
Press Releases
FAQs
PATIENTS
EVENT CALENDER
OPEN POSITIONS
CONTACT US
Patients
Investor Relations
PRESS ROOM
10/15/09
Protalix BioTherapeutics Announces Positive Top-line Results from its Phase III Clinical Trial of UPLYSO™ for the Treatment of Gaucher Disease
09/22/09
Protalix Reports Preclinical Data on Anti-TNF Follow-on Biologic Arthritis Drug
09/14/09
Protalix Completes Pivotal Phase III Trial for prGCD for the Treatment of Gaucher Disease
09/08/09
FDA Grants Protalix Orphan Drug Designation for prGCD
08/25/09
Protalix Receives FDA Fast Track Designation for prGCD
08/17/09
U.S. Food and Drug Administration Approves Protalix's Treatment Protocol for prGCD
08/06/09
Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences
07/14/09
Protalix Holds Pre-NDA Meeting with FDA for prGCD
07/06/09
Protalix Approached by the FDA to Consider Submitting a Treatment Protocol for the Use of prGCD in Patients with Gaucher Disease Allowing Expanded Access to prGCD
PROTALIX BIOTHERAPEUTICS
2 Snunit St., Science Park,
POB 455, Carmiel 20100, Israel.
T: +972-4-9028100
F: +972-4-988-9489
E:
info@protalix.com
patient-info@protalix.com
© 2007 Protalix Biotherapeutics. All Rights Reserved.